June 4, 2026
The Vet Bill Nobody Skips
IDEXX Laboratories and the Recession-Proof Rise of Pet Healthcare
From the Desk of InvestorPlace: I don’t forward many outside notes to my readers. But this one from my colleague Luke Lango stopped me cold. If you’ve been following the OpenAI IPO story – and most of our readers have – what Luke is about to share could completely change how you approach it. Please read this carefully before IPO day arrives.
Dear Reader,
It’s no longer theoretical. It’s officially in motion.
CNBC just announced that OpenAI – the inventors of ChatGPT – are about to file the confidential paperwork to go public.
And it could be the largest IPO in American history.
We all knew it was coming. But here’s what almost everyone is about to get wrong.
They’ll rush to buy OpenAI the moment it hits the market.
And if history is any guide, most of them will regret it.
In nearly every blockbuster tech IPO of the last 15 years, the people who bought on day one underperformed.
While a small group of other folks made as much as 3,900% on a little known investment connected to the IPO.
I call it the Pre-IPO Backdoor.
In my view, it’s one of the best moneymaking opportunities out there.
It rarely comes around. You only see it when a huge tech company goes public.
And it’s about to open again, thanks to the OpenAI IPO.
There’s only one catch. You need to get in before OpenAI actually goes public.
And that could happen very, very soon.
For the full story – and a free ticker you can invest in TODAY – click here.
Sincerely,
Luke Lango
Senior Technology Analyst, InvestorPlace
P.S. There’s every chance the OpenAI IPO will be the biggest in American history. And that means the Pre-IPO Backdoor opportunities could be the biggest ever too. You may never see another opportunity like this in your lifetime. For your free ticker, click here now.
The Vet Bill Nobody Skips
There is a category of consumer spending that barely flinches during recessions. Not luxury goods. Not tech subscriptions. It is veterinary diagnostics, and the numbers behind it are getting harder to ignore.
The underlying driver is structural, not cyclical. According to 2025 survey data published by Grand View Research, 97% of pet owners describe their animals as part of the family. One in three now spends more on their pet each month than on their own health and wellness. That is not a trend. That is a permanent behavioral shift, and it is repricing the entire companion animal healthcare sector upward.
The Market Behind the Move
U.S. pet industry expenditures reached $152 billion in 2024, with veterinary care alone accounting for $39.8 billion of that total. The global veterinary services market was valued at $145.65 billion in 2024 and is projected to reach $281.93 billion by 2033, growing at a CAGR of 7.66%. Within that, the U.S. companion animal health market is expanding even faster, estimated at $8.01 billion in 2024 and projected to grow at a 9.87% CAGR through 2030. The veterinary care segment of North American pet care is expected to grow at 10.3% annually through 2033.
What is interesting is where most of that money eventually flows. Not into food. Not into grooming. Into diagnostics, pharmaceuticals, and the instruments that make accurate treatment possible at the point of care.
Why IDXX Sits at the Center
IDEXX Laboratories (NASDAQ: IDXX) develops and manufactures the diagnostic equipment, consumables, and software that veterinary practices worldwide depend on every day. Their business model is built around a classic razor-and-blade structure: place premium instruments into clinics, then generate high-margin, recurring revenue from the consumables those instruments require. Practices do not switch platforms easily. The switching costs are real, customer retention is high, and the revenue base is sticky by design.
Full year 2025 revenue reached $4.304 billion, a 10% increase on both a reported and organic basis. EPS came in at $13.08, up 23% reported and 14% on a comparable basis. CAG Diagnostics recurring revenue grew 9% reported and 8% organically for the year. IDEXX VetLab consumables alone generated 17% revenue growth reported and 15% organically, driven by recent product launches and a 12% expansion in the global premium instrument installed base. Q4 2025 delivered $1.091 billion in revenue, up 14% reported and 12% organic, with EPS of $3.08 rising 18% year over year.
Slight tangent, but it matters: IDEXX also recently launched its third menu expansion for the Catalyst platform in under a year, adding the Catalyst Cortisol Test in June 2025, targeting endocrine diagnostics for Addison’s disease and Cushing’s syndrome in dogs. That pace of innovation on a core platform is not accidental. It deepens the moat and increases testing utilization per visit, which is exactly the metric that drives consumable revenue.
For 2026, management has guided revenue of $4.632 billion to $4.720 billion and EPS of $14.29 to $14.80, reflecting continued organic gains and 40 to 90 basis points of reported operating margin expansion. The international segment showed particular strength in 2025, with Q1 international organic growth running at 8.5%, helping offset softer U.S. clinical visit volume early in the year.
What This Means Structurally
The pet humanization thesis is not a feel-good story dressed up as an investment angle. It is a measurable, multi-decade behavioral shift showing up consistently in spending data across income brackets and geographies. When a pet owner brings a sick dog into a clinic, they are not comparison shopping the diagnostic panel. They approve whatever the vet recommends. That dynamic insulates IDEXX from the demand destruction that hits most consumer-facing businesses during downturns.
The combination of a growing installed base, expanding consumable attach rates, accelerating innovation cadence, and a recurring revenue model that does not depend on new clinic acquisitions to grow is a rare set of attributes. Whether the macro picture brightens or deteriorates from here, the vet bill is one of the last things pet owners cut. IDEXX is the infrastructure underneath that decision.
Key Data Points to Watch
- FY2025 revenue: $4.304B (+10% reported and organic)
- FY2025 EPS: $13.08 (+14% comparable basis)
- IDEXX VetLab consumables: +17% reported, +15% organic in FY2025
- Global premium instrument installed base: +12% in FY2025
- 2026 revenue guidance: $4.632B to $4.720B
- 2026 EPS guidance: $14.29 to $14.80
- U.S. companion animal health market CAGR through 2030: 9.87%
- Global veterinary services market CAGR through 2033: 7.66%
The question for traders and long-term observers alike is not whether pet healthcare spending continues to grow. That part is settled. The question is which companies own the infrastructure layer that captures it. Right now, IDEXX owns a significant piece of that infrastructure worldwide.
